Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04187105 · ClinicalTrials.gov registry record · Phase 2
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
A Phase 2 study of Acute Leukemia and MDS, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT04187105 is a Phase 2 study of Acute Leukemia and MDS that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 27 participants, below the 462-participant average among 37 other Acute Leukemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04187105, a Phase 2 study of Acute Leukemia and MDS, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total Marrow Irradiation (IM-TMI).
Conditions Studied
Interventions
- RADIATION Conditioning regimen with half-matched (haploidentical) stem cell transplant
- DRUG Conditioning regimen with half-matched (haploidentical) stem cell transplant
- DEVICE Conditioning regimen with half-matched (haploidentical) stem cell transplant
- OTHER Conditioning regimen with half-matched (haploidentical) stem cell transplant
Study Locations (1)
Illinois
- University of Illinois Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04187105
The ClinicalTrials.gov registry entry for NCT04187105 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 37 other Acute Leukemia trials with a reported enrollment target (94% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Conditioning regimen with half-matched (haploidentical) stem cell transplant is the first listed.
NCT04187105 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04187105 about?
NCT04187105 is a clinical study titled "BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)". This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total M...
What is the current status of trial NCT04187105?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-01-27. Estimated completion is 2026-12.
What conditions does trial NCT04187105 study?
This clinical trial studies the following conditions: Acute Leukemia, MDS.
What interventions are being tested in trial NCT04187105?
The interventions under investigation include: Conditioning regimen with half-matched (haploidentical) stem cell transplant (RADIATION), Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG), Conditioning regimen with half-matched (haploidentical) stem cell transplant (DEVICE), Conditioning regimen with half-matched (haploidentical) stem cell transplant (OTHER).
Who is sponsoring clinical trial NCT04187105?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04187105 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.